On August 6, WUXI BIO rose 3.1% in regular trading, trading at HKD 41.96/share, with turnover of HKD 687 million.

On the news front, sector peer WuXi AppTec previously reported strong interim results, posting first-half revenue of RMB 28.897 billion, up 38.93% year-over-year, with adjusted net profit surging 89.39% YoY, driving broad-based strength across the CXO sector. WUXI BIO's board is scheduled to review interim results on August 25, with the market holding positive earnings expectations. Institutional research indicates the CXO upcycle has progressively entered an earnings realization phase, with global innovative drug primary market financing reaching USD 26.75 billion in H1, up 58.5% YoY, continuing to support sector valuation recovery.

Additionally, the company's MFG8 drug substance facility recently obtained FDA PLI approval, and the company has been conducting active share buybacks, reflecting management confidence in its long-term outlook.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)